VASCULAR DEMENTIA - THE PROBLEM OF GENERAL PRACTITIONER


如何引用文章

全文:

详细

The article discusses the clinical significance and approaches to the treatment of cerebrovascular diseases in the physician's practice. The vascular dementia (VD), which first must be recognized by general practitioner, inevitably lead to social maladjustment, promotes a discernible decline in adherence to treatment; in this connection, the course of majority of chronic diseases worsens. The contributing factors for VD and other cognitive impairments (arterial hypertension, diabetes mellitus, obesity, etc.), possible ways of their prevention and treatment are considered. Results of clinical studies show that pentoxifylline is one of the pathogenetic action drugs which inhibit the progression of cognitive dysfunction. It is noted that long-term use of pentoxifylline allows to reduce the rate of development of VD in patients after acute cerebrovascular events, including recurrent events.

作者简介

Viktor Fomin

V Fomin

参考

  1. Лазебник Л.Б. Старение и полиморбидность // Consilium Medicum 2005. № 7(12). C. 23-26.
  2. Дамулин ИВ. Сосудистая деменция // Неврологич. журн. 1999. № 3. C. 4-11.
  3. Яхно Н.Н. Когнитивные расстройства в неврологической клинике // Невролог. журн. 2006. № 11(1). C. 4-12.
  4. Waldstein SR, Wendell CR. Neurocognitive function and cardiovascular disease. J Alzheimers Dis 2010;20(3):833-42.
  5. Baldwin RC. Preventing late-life depression: a clinical update. Int Psychogeriatr 2010;22(8):1216-24.
  6. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Системные гипертензии 2010. № 3. C. 5-26.
  7. Kloppenborg RP, van den Berg E, Kappelle LJ, et al. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008;585(1):97-108.
  8. Hassing LB, Johansson B, Nilsson SE, et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 2002;14(3) 239-48.
  9. Roman GC. Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis 2005;20(2):91-100.
  10. Di Carlo A, Baldereschi M, Amaducci L, et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Geriatr Soc 2000;48(7):775-82.
  11. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008;7(9):812-26.
  12. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310(6985):970-73.
  13. Ishii H, Meguro K, Yamaguchi S, et al. Prevalence and cognitive performances of vascular cognitive impairment no dementia in Japan: the Osaki-Tajiri Project. Eur J Neurol 2007;14(6):609-16.
  14. Fernandez-Martinez M, Castro J, Molano A, et al. Prevalence of neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. Curr Alzheimer Res 2008;5(1):61-69.
  15. Sicras A, Rejas J, Arco S, et al. Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting. Dement Geriatr Cogn Disord 2005;19(5-6):305-15.
  16. Rocca WA, Hofman A, Brayne C, et al. The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies. EURODEM-Prevalence Research Group. Ann Neurol 1991;30(6):817-24.
  17. Flaker GC, Pogue J, Yusuf S, et al. Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) Investigators. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ. Cardiovasc Qual Outcomes 2010;3(3):277-83.
  18. Richards SS, Emsley CL, Roberts J, et al. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 2000;48(9):1035-41.
  19. McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Сochrane Database Syst Rev 2009;(4):CD004034.
  20. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
  21. Skoog I, Lithell H, Hansson L, et al. SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005;18(8):1052-59.
  22. Gustafson DR. Adiposity hormones and dementia. J Neurol Sci 2010;299(1-2):30-34.
  23. Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995;7(6):480-503.
  24. European Pentoxifylline Multi-Infarct Dementia Study Group. European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol 1996;36(5):315-21.
  25. Black RS, Barclay LL, Nolan KA, et al. Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 1992;40(3):237-44.
  26. Blume J, Rùhlmann KU, de la Haye R, et al. Treatment of chronic cerebrovascular disease in elderly patients with pentoxifylline. J Med 1992;23(6):417-32.
  27. Sha MC, Callahan CM. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis Assoc Disord 2003;17(1):46-54.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##